Edition:
United Kingdom

BeiGene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

115.58USD
8:19pm GMT
Change (% chg)

$12.95 (+12.62%)
Prev Close
$102.63
Open
$109.46
Day's High
$119.60
Day's Low
$109.46
Volume
464,586
Avg. Vol
116,895
52-wk High
$119.60
52-wk Low
$31.78

Select another date:

BRIEF-BeiGene prices follow-on offering of 7.4 mln American depositary shares at $101 per ADS

* ‍PRICING OF FOLLOW-ON PUBLIC OFFERING OF 7. 4 MILLION AMERICAN DEPOSITARY SHARES AT A PRICE TO PUBLIC OF $101.00 PER ADS​ Source text for Eikon: Further company coverage:

BRIEF-Beigene Announces Proposed Public Offering

* BEIGENE LTD - ‍PUBLIC OFFERING OF ITS AMERICAN DEPOSITARY SHARES (ADSS), EACH REPRESENTING 13 OF ITS ORDINARY SHARES, PAR VALUE $0.0001 PER SHARE​

BRIEF-Beigene And Boehringer Ingelheim Announce Commercial Supply Agreement For Tislelizumab

* BEIGENE AND BOEHRINGER INGELHEIM ANNOUNCE COMMERCIAL SUPPLY AGREEMENT FOR ANTI-PD-1 ANTIBODY TISLELIZUMAB

BRIEF-Beigene And Mirati Therapeutics Announce Exclusive License Agreement For Sitravatinib In The Asia Pacific Region

* BEIGENE AND MIRATI THERAPEUTICS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR SITRAVATINIB IN THE ASIA PACIFIC REGION

BRIEF-Beigene Initiates Global Phase 3 Trial Of Anti-PD-1 Antibody Tislelizumab In Patients With Hepatocellular Carcinoma

* BEIGENE INITIATES GLOBAL PHASE 3 TRIAL OF ANTI-PD-1 ANTIBODY TISLELIZUMAB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA Source text for Eikon: Further company coverage:

BRIEF-BeiGene Initiates Pivotal Trial Of PARP Inhibitor Pamiparib In China

* BEIGENE INITIATES PIVOTAL TRIAL OF PARP INHIBITOR PAMIPARIB (BGB-290) IN CHINA IN PATIENTS WITH OVARIAN CANCER Source text for Eikon: Further company coverage:

BRIEF-Beigene expands global pivotal program for BTK inhibitor BGB-3111

* Beigene expands global pivotal program for BTK inhibitor BGB-3111

BRIEF-Beigene Ltd qtrly ‍net income attributable to common shareholders per ADS, diluted $2.54​

* Beigene Ltd - qtrly ‍net income attributable to common shareholders per ads, diluted $2.54​ Source text for Eikon: Further company coverage:

BRIEF-Celgene Corp reports 5.6 percent passive stake in BeiGene as of Aug 31 - SEC filing‍​

* Celgene Corp reports 5.6 percent passive stake in BeiGene as of Aug 31 - SEC filing‍​ Source text : (http://bit.ly/2guND0F) Further company coverage:

BRIEF-Beigene prices 2.46 mln ADS at $71 per unit

* Pricing of its follow-on public offering of 2,465,000 american depositary shares at a price to public of $71.00 per ads Source text for Eikon: Further company coverage:

Select another date: